The Next Step of Their Control Is Here …

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

Richard Daniell Biography and Net Worth

VP of Teva Pharmaceutical Industries

Richard Daniell became Executive Vice President, European Commercial in November 2017, leading all activities of Teva Europe’s Generic, Specialty and over the counter (OTC) businesses as well as our Teva API and Medis B2B units.

With headquarters in The Netherlands, Teva Europe employs approximately 19,000 people in the region and covers 36 countries. Teva is Europe’s biggest provider of tried-and-trusted generic medicine, a leading provider of OTC medicines and a recognized innovator in CNS, respiratory medicines and biopharmaceuticals.

Before assuming this responsibility, Richard headed up Teva Europe Generics. Prior to that he served as Chief Operating Officer of International Markets and led the integration of the Actavis Generics business into Teva globally. Before that he served as General Manager for the United Kingdom and Ireland.

Richard received his B.Sc. degree in chemistry from the University of Auckland, New Zealand.

What is Richard Daniell's net worth?: The estimated net worth of Richard Daniell is at least $153,152.40 as of September 9th, 2020. Mr. Daniell owns 11,098 shares of Teva Pharmaceutical Industries stock worth more than $153,152 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Daniell may own. Learn More about Richard Daniell's net worth.
How do I contact Richard Daniell?: The corporate mailing address for Mr. Daniell and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Richard Daniell's contact information.
Has Richard Daniell been buying or selling shares of Teva Pharmaceutical Industries?: Richard Daniell has not been actively trading shares of Teva Pharmaceutical Industries in the last ninety days. Most recently, Richard Daniell sold 333 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $8.98, for a transaction totalling $2,990.34. Following the completion of the sale, the vice president now directly owns 11,098 shares of the company's stock, valued at $99,660.04. Learn More on Richard Daniell's trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 480,586 shares worth more than $5,931,942.06. The most recent insider tranaction occured on March, 5th when EVP Mark Sabag sold 100,000 shares worth more than $1,352,000.00. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 3/5/2024.

Richard Daniell Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2020	Sell	333	$8.98	$2,990.34	11,098
3/3/2020	Sell	991	$11.77	$11,664.07	10,710
9/18/2019	Sell	1,176	$7.82	$9,196.32	2,852
9/9/2019	Sell	333	$7.16	$2,384.28	696
3/12/2019	Sell	715	$15.69	$11,218.35	715
3/4/2019	Sell	2,098	$16.88	$35,414.24	2,098
9/18/2018	Sell	2,488	$23.69	$58,940.72	2,488
9/10/2018	Sell	696	$21.25	$14,790.00	696
3/19/2018	Sell	1,297	$17.89	$23,203.33	1,297
3/5/2018	Sell	1,108	$19.28	$21,362.24

Richard Daniell Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $13.80

$13.33

$13.98

50 Day Range

MA: $13.50

$12.78

$14.44

2 Week Range

Now: $13.80

$7.09

$14.47

Volume

10,278,343 shs

Average Volume

10,553,149 shs

Market Capitalization

$15.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05